Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Proof-of-concept, National, Multicenter, Randomized, Double-blind Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

NCT07843056 is registered in ClinicalTrials.gov with EMS as lead sponsor.

NCT NCT07843056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07843056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Proof-of-concept, National, Multicenter, Randomized, Double-blind Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.
Lead sponsor
EMS
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2022
Completion date
March 23, 2026
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophenia disorder